CYTOF (Altamira Therapeutics) Shares Buyback Ratio %: -113.96 (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Altamira Therapeutics Shares Buyback Ratio %?

Altamira Therapeutics CYTOF Shares Buyback Ratio % is -113.96 as of Sep. 02, 2026. The stock has 4 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Altamira Therapeutics's current shares buyback ratio was -113.96%.

Altamira Therapeutics Shares Buyback Ratio % Related Terms

Altamira Therapeutics Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Altamira Therapeutics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altamira Therapeutics Shares Buyback Ratio % Chart

Altamira Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -190.00 -27.59 -59.46 -2,405.08 -215.43

Altamira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -574.58 -271.36 -80.72 -74.54 -22.59

Altamira Therapeutics Shares Buyback Ratio % Calculation

Altamira Therapeutics's Shares Buyback Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2023 ) - Shares Outstanding (EOP) (A: Dec. 2024 )) / Shares Outstanding (EOP) (A: Dec. 2023 )
=(1.478 - 4.662) / 1.478
=-215.43%

Altamira Therapeutics's Shares Buyback Ratio for the quarter that ended in Jun. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Jun. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(4.662 - 5.715) / 4.662
=-22.59%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -113.96 mean?
Altamira Therapeutics (CYTOF) has a Shares Buyback Ratio % of -113.96 as of Sep. 02, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Altamira Therapeutics and its competitors.
Is Altamira Therapeutics' Shares Buyback Ratio % too high?
Altamira Therapeutics' current Shares Buyback Ratio % is -113.96.
How does Altamira Therapeutics' Shares Buyback Ratio % compare to CPMV and LYRA?
Altamira Therapeutics' Shares Buyback Ratio % of -113.96 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Altamira Therapeutics and its competitors. Altamira Therapeutics's current Shares Buyback Ratio % is -113.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (CYTOF) has a current Shares Buyback Ratio % of -113.96. The current Shares Buyback Ratio % is -113.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Altamira Therapeutics (CYTOF), the current Shares Buyback Ratio % is -113.96 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altamira Therapeutics Business Description

Address 2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.